Hospira, Inc, Initiates Recall of One Lot of 2% Lidocaine HCl Injection

 Hospira, Inc, of Lake Forest, IL, has initiated a voluntary recall for one lot of Lidocaine HCl Injection, USP 2%, 5 mL Single-Dose Vial, National Drug Code 0409-4276-01, Lot 32-135-DD due to the presence of particulate matter. Hospira initiated the recall after a reddish orange particulate was observed on the inner surface and floating in the solution. This recall is in addition to a similar recall of 1% Lidocaine HCI Injection that Hospira initiated on October 4, 2013. 

According to FDA, the recalled product was distributed to distributors/wholesalers, hospitals, and pharmacies located in Alaska, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Nevada, New Jersey, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, and Wisconsin between September 2013 and through October 2013. FDA advises that health care providers stop use and quarantine the product. To arrange return of the product, providers may call Stericycle at 866/364-8812 between the hours of 8 AM and 5 PM  ET, Monday through Friday. Adverse reactions may be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program
quoted from here